Synaptogenix Inc (SNPX)
4.61
+0.24
(+5.49%)
USD |
NASDAQ |
Jun 14, 16:00
4.61
0.00 (0.00%)
After-Hours: 20:00
Synaptogenix Enterprise Value: -21.76M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 14, 2024 | -21.76M |
June 13, 2024 | -22.06M |
June 12, 2024 | -22.03M |
June 11, 2024 | -22.26M |
June 10, 2024 | -22.31M |
June 07, 2024 | -22.30M |
June 06, 2024 | -22.30M |
June 05, 2024 | -22.31M |
June 04, 2024 | -22.09M |
June 03, 2024 | -21.77M |
May 31, 2024 | -21.83M |
May 30, 2024 | -21.97M |
May 29, 2024 | -22.03M |
May 28, 2024 | -21.78M |
May 24, 2024 | -21.88M |
May 23, 2024 | -21.67M |
May 22, 2024 | -21.49M |
May 21, 2024 | -21.34M |
May 20, 2024 | -21.48M |
May 17, 2024 | -21.59M |
May 16, 2024 | -21.39M |
May 15, 2024 | -21.64M |
May 14, 2024 | -21.57M |
May 13, 2024 | -21.87M |
May 10, 2024 | -22.48M |
Date | Value |
---|---|
May 09, 2024 | -22.33M |
May 08, 2024 | -22.40M |
May 07, 2024 | -22.36M |
May 06, 2024 | -22.33M |
May 03, 2024 | -21.92M |
May 02, 2024 | -22.28M |
May 01, 2024 | -22.20M |
April 30, 2024 | -22.30M |
April 29, 2024 | -22.61M |
April 26, 2024 | -22.53M |
April 25, 2024 | -22.65M |
April 24, 2024 | -22.50M |
April 23, 2024 | -22.48M |
April 22, 2024 | -22.71M |
April 19, 2024 | -22.74M |
April 18, 2024 | -22.39M |
April 17, 2024 | -22.23M |
April 16, 2024 | -22.40M |
April 15, 2024 | -22.65M |
April 12, 2024 | -22.36M |
April 11, 2024 | -22.21M |
April 10, 2024 | -22.34M |
April 09, 2024 | -22.08M |
April 08, 2024 | -21.59M |
April 05, 2024 | -22.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-28.87M
Minimum
Mar 22 2023
52.91M
Maximum
Oct 12 2021
-0.2335M
Average
5.271M
Median
Feb 05 2021
Enterprise Value Benchmarks
CEL-SCI Corp | 65.10M |
AIM ImmunoTech Inc | 15.35M |
IGC Pharma Inc | 25.36M |
NovaBay Pharmaceuticals Inc | 3.382M |
Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -0.2067M |
Total Expenses (Quarterly) | 1.692M |
EPS Diluted (Quarterly) | -0.41 |
Earnings Yield | -806.6% |